Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls

Psychological Medicine

Volumn 47, Issue 7, 2017, Pages 1311-1322

  Woolley, J D ^a,b   Chuang, B ^a,b   Fussell, C ^a,b   Scherer, S ^c   Biagianti, B ^b   Fulford, D ^d   Mathalon, D H ^a,b   Vinogradov, S ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Southern California   (United States)

^d BOSTON UNIVERSITY   (United States)

Author keywords

Blunted affect; Facial expressivity; Oxytocin; Schizophrenia; Social cognition; Trustworthiness

Indexed keywords

NEUROPEPTIDE; OXYTOCIN;

ADULT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FACIAL EXPRESSION; FACIAL RECOGNITION; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PERCEPTION; PHYSIOLOGY; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TRUST; YOUNG ADULT;

ADMINISTRATION, INTRANASAL; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FACIAL EXPRESSION; FACIAL RECOGNITION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDES; OXYTOCIN; SCHIZOPHRENIA; SOCIAL PERCEPTION; TRUST; YOUNG ADULT;

EID: 85009760460     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291716003433     Document Type: Article

References (61)

1. Abu-Akel A, Fischer-Shofty M, Levkovitz Y, Decety J, Shamay-Tsoory S (2014). The role of oxytocin in empathy to the pain of conflictual out-group members among patients with schizophrenia. Psychological Medicine 44, 3523-3532.
2. Adolphs R, Tranel D, Damasio AR (1998). The human amygdala in social judgment. Nature 393, 470-474.
3. Aghevli MA, Blanchard JJ, Horan WP (2003). The expression and experience of emotion in schizophrenia: a study of social interactions. Psychiatry Research 119, 261-270.
4. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC (2010). Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 67, 255-262.
5. Anticevic A, Repovs G, Barch DM (2012). Emotion effects on attention, amygdala activation, functional connectivity in schizophrenia. Schizophrenia Bulletin 38, 967-980.
6. Baas D, Aleman A, Vink M, Ramsey NF, De Haan EH, Kahn RS (2008a). Evidence of altered cortical and amygdala activation during social decision-making in schizophrenia. NeuroImage 40, 719-727.
7. Baas D, Van't Wout M, Aleman A, Kahn R (2008b). Social judgement in clinically stable patients with schizophrenia and healthy relatives: behavioural evidence of social brain dysfunction. Psychological Medicine 38, 747-754.
8. Barraza JA, Zak PJ (2009). Empathy toward strangers triggers oxytocin release and subsequent generosity. Annals of the New York Academy of Sciences 1167, 182-189.
9. Berenbaum H, Oltmanns TF (1992). Emotional experience and expression in schizophrenia and depression. Journal of Abnormal Psychology 101, 37-44.
10. Blanchard JJ, Cohen AS (2006). The structure of negative symptoms within schizophrenia: implications for assessment. Schizophrenia Bulletin 32, 238-245.
11. Busnelli M, Dagani J, Girolamo G, Balestrieri M, Pini S, Saviotti FM, Scocco P, Sisti D, Rocchi M, Chini B (2016). Unaltered oxytocin and vasopressin plasma levels in patients with schizophrenia after 4 months of daily treatment with intranasal oxytocin. Journal of Neuroendocrinology 28. Published online 25 April 2016. doi:10. 1111/jne. 12359.
12. Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, Moore L, Alvares GA, Redoblado Hodge MA, Guastella AJ (2015). A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis. Schizophrenia Bulletin 41, 483-493.
13. Cohen AS, Alpert M, Nienow TM, Dinzeo TJ, Docherty NM (2008). Computerized measurement of negative symptoms in schizophrenia. Journal of Psychiatry Research 42, 827-836.
14. Cohen AS, Minor KS (2010). Emotional experience in patients with schizophrenia revisited: meta-analysis of laboratory studies. Schizophrenia Bulletin 36, 143-150.
15. Couture SM, Penn DL, Addington J, Woods SW, Perkins DO (2008). Assessment of social judgments and complex mental states in the early phases of psychosis. Schizophrenia Research 100, 237-241.
16. Dagani J, Sisti D, Abelli M, Di Paolo L, Pini S, Raimondi S, Rocchi MB, Saviotti FM, Scocco P, Totaro S, Balestrieri M, de Girolamo G (2016). Do we need oxytocin to treat schizophrenia? A randomized clinical trial. Schizophrenia Research 172, 158-164.
17. Eckert SL, Diamond PM, Miller AL, Velligan DI, Funderburg LG, True JE (1996). A comparison of instrument sensitivity to negative symptom change. Psychiatry Research 63, 67-75.
18. Ekman P, Friesen WV (1976). Measuring facial movement. Environmental Psychology and Nonverbal Behavior 1, 56-75.
19. Feifel D, Macdonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A (2010). Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biological Psychiatry 68, 678-680.
20. Feifel D, Shilling PD, Macdonald K (2016). A review of oxytocin's effects on the positive, negative, cognitive domains of schizophrenia. Biological Psychiatry 79, 222-233.
21. First MB, Gibbon M, Spitzer RL, Williams JBW (2002). Structured Clinical Interview for DSM-IV-TR Axis I Disorders. Research Version, Patient Edition (SCID-I/P). New York State Psychiatric Institute: New York.
22. Foussias G, Siddiqui I, Fervaha G, Agid O, Remington G (2015). Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. Journal of Psychopharmacology 29, 116-126.
23. Gamer M, Büchel C (2012). Oxytocin specifically enhances valence-dependent parasympathetic responses. Psychoneuroendocrinology 37, 87-93.
24. Gibson CM, Penn DL, Smedley KL, Leserman J, Elliott T, Pedersen CA (2014). A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia. Schizophrenia Research 156, 261-265.
25. Green MF (2016). Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia. Journal of Clinical Psychiatry 77 (Suppl. 2), 8-11.
26. Gur RE, Kohler CG, Ragland JD, Siegel SJ, Lesko K, Bilker WB, Gur RC (2006). Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophrenia Bulletin 32, 279-287.
27. Gur RE, Loughead J, Kohler CG, Elliott MA, Lesko K, Ruparel K, Wolf DH, Bilker WB, Gur RC (2007). Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Archives of General Psychiatry 64, 1356-1366.
28. Hooker CI, Tully LM, Verosky SC, Fisher M, Holland C, Vinogradov S (2011). Can I trust you? Negative affective priming influences social judgments in schizophrenia. Journal of Abnormal Psychology 120, 98-107.
29. Horta de Macedo LR, Zuardi AW, Machado-De-Sousa JP, Chagas MH, Hallak JE (2014). Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task. Psychiatry Research 220, 125-128.
30. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
31. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A (2005). Oxytocin modulates neural circuitry for social cognition and fear in humans. Journal of Neuroscience 25, 11489-11493.
32. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005). Oxytocin increases trust in humans. Nature 435, 673-676.
33. Kring AM, Elis O (2013). Emotion deficits in people with schizophrenia. Annual Review of Clinical Psychology 9, 409-433.
34. Kring AM, Moran EK (2008). Emotional response deficits in schizophrenia: insights from affective science. Schizophrenia Bulletin 34, 819-834.
35. Kring AM, Neale JM (1996). Do schizophrenic patients show a disjunctive relationship among expressive, experiential, psychophysiological components of emotion? Journal of Abnormal Psychology 105, 249-257.
36. Kring AM, Sloan DM (2007). The Facial Expression Coding System (FACES): development, validation, utility. Psychological Assessment 19, 210-224.
37. Kring AM, Smith DA, Neale JM (1994). Individual differences in dispositional expressiveness: development and validation of the emotional expressivity scale. Journal of Personality and Social Psychology 66, 934-949.
38. Lambert B, Declerck CH, Boone C (2014). Oxytocin does not make a face appear more trustworthy but improves the accuracy of trustworthiness judgments. Psychoneuroendocrinology 40, 60-68.
39. Lepage M, Sergerie K, Benoit A, Czechowska Y, Dickie E, Armony JL (2011). Emotional face processing and flat affect in schizophrenia: functional and structural neural correlates. Psychological Medicine 41, 1833-1844.
40. Lukoff D, Liberman RP, Nuechterlein KH (1986). Symptom monitoring in the rehabilitation of schizophrenic patients. Schizophrenia Bulletin 12, 578-602.
41. Michelini LC, Marcelo MC, Amico J, Morris M (2003). Oxytocinergic regulation of cardiovascular function: studies in oxytocin-deficient mice. American Journal of Physiology-Heart and Circulatory Physiology 284, H2269-H2276.
42. Narum SR (2006). Beyond Bonferroni: less conservative analyses for conservation genetics. Conservation Genetics 7, 783-787.
43. Norman GJ, Cacioppo JT, Morris JS, Karelina K, Malarkey WB, Devries AC, Berntson GG (2011). Selective influences of oxytocin on the evaluative processing of social stimuli. Journal of Psychopharmacology 25, 1313-1319.
44. Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Jarskog LF, Penn DL (2011). Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia. Schizophrenia Research 132, 50-53.
45. Peterman JS, Bekele E, Bian D, Sarkar N, Park S (2015). Complexities of emotional responses to social and non-social affective stimuli in schizophrenia. Frontiers in Psychology 6, 320.
46. Pinkham AE, Hopfinger JB, Pelphrey KA, Piven J, Penn DL (2008). Neural bases for impaired social cognition in schizophrenia and autism spectrum disorders. Schizophrenia Research 99, 164-175.
47. Repantis D, Laisney O, Heuser I (2010). Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review. Pharmacological Research 61, 473-481.
48. Scherer S, Stratou G, Lucas G, Mahmoud M, Boberg J, Gratch J, Morency L-P (2014). Automatic audiovisual behavior descriptors for psychological disorder analysis. Image and Vision Computing 32, 648-658.
49. Serretti A, Calati R, Goracci A, Di Simplicio M, Castrogiovanni P, De Ronchi D (2010). Antidepressants in healthy subjects: what are the psychotropic/psychological effects? European Neuropsychopharmacology 20, 433-453.
50. Shin NY, Park HY, Jung WH, Park JW, Yun JY, Jang JH, Kim SN, Han HJ, Kim SY, Kang DH, Kwon JS (2015). Effects of oxytocin on neural response to facial expressions in patients with schizophrenia. Neuropsychopharmacology 40, 1919-1927.
51. Shrout PE, Fleiss JL (1979). Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin 86, 420-428.
52. Sripada CS, Phan KL, Labuschagne I, Welsh R, Nathan PJ, Wood AG (2013). Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. International Journal of Neuropsychopharmacology 16, 255-260.
53. Sweet LH, Primeau M, Fichtner CG, Lutz G (1998). Dissociation of affect recognition and mood state from blunting in patients with schizophrenia. Psychiatry Research 81, 301-308.
54. Taylor SF, Phan KL, Decker LR, Liberzon I (2003). Subjective rating of emotionally salient stimuli modulates neural activity. NeuroImage 18, 650-659.
55. Tremeau F, Malaspina D, Duval F, Correa H, Hager-Budny M, Coin-Bariou L, Macher JP, Gorman JM (2005). Facial expressiveness in patients with schizophrenia compared to depressed patients and nonpatient comparison subjects. American Journal of Psychiatry 162, 92-101.
56. Tsapakis EM, Dimopoulou T, Tarazi FI (2015). Clinical management of negative symptoms of schizophrenia: an update. Pharmacology and Therapeutics 153, 135-147.
57. Walker EF, Grimes KE, Davis DM, Smith AJ (1993). Childhood precursors of schizophrenia: facial expressions of emotion. American Journal of Psychiatry 150, 1654-1660.
58. Weiser M, Saporta L, Levi L, Feldman R (2015). S. 13. 03 RCT administering oxytocin for schizophrenia, a three week add-on study. European Neuropsychopharmacology 25 (Suppl. 2), S130-S131.
59. Winston JS, Strange BA, O'Doherty J, Dolan RJ (2002). Automatic and intentional brain responses during evaluation of trustworthiness of faces. Nature Neuroscience 5, 277-283.
60. Wolf K, Mass R, Kiefer F, Eckert K, Stritzky AV, Haasen C, Wiedemann K, Naber D (2005). The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia-preliminary results of a facial electromyogram study. Journal of Clinical Psychopharmacology 25, 278-281.
61. Woolley JD, Chuang B, Lam O, Lai W, O'Donovan A, Rankin KP, Mathalon DH, Vinogradov S (2014). Oxytocin administration enhances controlled social cognition in patients with schizophrenia. Psychoneuroendocrinology 47, 116-125.